C. Zamagni

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

Luca Gianni, Chiun‐Sheng Huang, Daniel Egle et al. · Annals of Oncology · 2022 · 386 citations · Full text

Medicine, Oncology, Pharmacology +15

LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial

Giampaolo Bianchini, Chiun‐Sheng Huang, Daniel Egle et al. · Annals of Oncology · 2020 · 51 citations

Medicine, Immunology, Oncology +14

CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study

A. Martoni, C. Zamagni, B Bellanova et al. · European Journal of Cancer · 1995 · 31 citations

Medicine, Oncology, Breast Oncology +15

The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer

Matteo Dugo, Chiun‐Sheng Huang, Daniel Egle et al. · Clinical Cancer Research · 2024 · 22 citations · Full text

Medicine, Immunology, Oncology +17

Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry

Massimo Martino, Alberto Ballestrero, Alberto Zambelli et al. · Bone Marrow Transplantation · 2012 · 20 citations

Medicine, Oncology, Breast Oncology +16